Rexulti (brexpiprazole) is an oral tablet approved to treat agitation associated with dementia due to Alzheimer's disease. Agitation means pacing, restlessness, verbal outbursts, or aggression that requires medication. The U.S.
Food and Drug Administration called it the first FDA-approved treatment for that indication in its May 2023 approval notice. The approval expanded a drug first used for other psychiatric conditions. Dosing starts low and builds over weeks toward 2 mg once daily. Improvement was measured over 12 weeks in the supporting trials.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who this approval covers
- What the trials showed
- How dosing builds over weeks
- Safety limits to discuss first
Who this approval covers
This use is specific to agitation with dementia due to Alzheimer's disease. It does not cover all dementia behaviors or all types of dementia. The supporting trials enrolled patients ages 51 to 90 with probable Alzheimer's dementia and agitation requiring medication.
Families often face shouting, hitting, resisting care, or severe restlessness. Those symptoms can make home care and daily routines unsafe. A clinician decides whether medication fits that pattern.
What the trials showed
Effectiveness was tested in two 12-week, randomized, double-blind, placebo-controlled, fixed-dose studies. Pharmacy Times, reporting FDA data, found that patients taking 2 mg or 3 mg daily had greater improvement than placebo on agitation scores by week 12 in its summary of the FDA data.
The measure was change from baseline in Cohen-Mansfield Agitation Inventory total score. That scale rates observable agitated behaviors. Results reflected average group improvement, not a fixed benefit for each person.
How dosing builds over weeks
The National Library of Medicine DailyMed label sets a slow start, not a full dose on day one, described in the DailyMed Rexulti label. Expect titration and regular check-ins during the first month.
Plan for daily use rather than quick relief. Bring a short log of sleep, agitation episodes, falls, appetite, and missed doses to each visit.
- Days 1-7: 0.5 mg orally once daily
- Days 8-14: 1 mg orally once daily
- Day 15 onward: 2 mg orally once daily as the target dose
- Maximum: 3 mg once daily, only after at least 14 days at 2 mg based on response and tolerability
Safety limits to discuss first
Rexulti carries a boxed warning about higher mortality when antipsychotics treat dementia-related psychosis in older adults. The label also warns about cerebrovascular events including stroke. The drug is not approved for dementia-related psychosis without agitation due to Alzheimer's disease.
Ask what signs should prompt an urgent call. Review stroke history, blood pressure, swallowing problems, sedation, and fall risk. Take it once daily with or without food as maintenance therapy rather than as-needed.
